US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting Approval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with best supportive care Basel, 15 October 2021 – Roche (SIX: RO, ROG; OTCQX:... Read more